EU RESEARCH PROJECT TARGETS CANCER PROTEIN IN DRUG THERAPY TESTS
January 1st, 2007
BY KEITH NUTHALLA EUROPEAN Union (EU) research project is targeting a receptor molecule protein called CD40 commonly found on cancerous cells, in developing a drug stimulating immune systems into attacking tumours. The Apotherapy project includes German pharmaceutical company Novosom, the University of Crete Medical School, in Greece, and scientists from universities in Helsinki and Uppsala, Finland. They aim to create a drug binding with CD40 that stimulates dendritic cell production, in turn producing proteins activating immune systems to fight cancer. ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.